Prurigo Nodularis Market Research Report | Prurigo Nodularis Market Analysis

The total prevalent population of Prurigo Nodularis in the seven major markets was found to be 689,760 in 2017. Among the European countries, Germany had the highest prevalent population of Prurigo Nodularis (PN) with 103,004 cases, followed by France with 57,996 cases in 2017. Besides, Spain had the lowest prevalent population with 44,273 cases in 2017. It has been observed that most of the patients with Atopic Prurigo Nodularis account for 75% of the total diagnosed Prurigo Nodularis cases, followed by Nonatopic Prurigo Nodularis (25%) in the United States. In 2017, there were 116,653 Atopic PN and 38,884 Nonatopic PN patients. Some of the key companies in the Prurigo Nodularis market include Menlo Therapeutics, Trevi Therapeutics, Kiniksa Pharmaceuticals, Galderma, Sanofi, and others.